SCHEMBL3015598

SCHEMBL3015598

O=S(=O)(c1ccc(Cl)cc1Cl)N1CCN(c2nc(Cc3ccc(F)c(Cl)c3)cs2)CC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 4/20 0.44
HSD11B1 P28845 1/20 0.43
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 4/20 0.39
LMNA P02545 3/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
LPAR1 Q92633 1/20 0.39
LPAR2 Q9HBW0 1/20 0.39
AR P10275 1/20 0.39
KDM2B Q8NHM5 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
RAB9A P51151 1/20 0.37
POLB P06746 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011722 0.94 TRPV4 (0.44) TRPV4HSD11B1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3007155 0.93 TRPV4 (0.43) TRPV4HSD11B1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3014045 0.93 ALDH1A1 (0.43) TRPV4HSD11B1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3009899 0.92 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA
SCHEMBL3008939 0.92 TRPV4 (0.46) TRPV4HSD11B1ALDH1A1L3MBTL1GAA
SCHEMBL3003595 0.92 ALDH1A1 (0.38) TRPV4HSD11B1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3021382 0.91 TRPV4 (0.48) TRPV4HSD11B1ALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL3017801 0.90 KMT2A (0.45) TRPV4ALDH1A1SMN1; SMN2L3MBTL1MAPT
SCHEMBL3010878 0.90 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2L3MBTL1MAPTLMNA
SCHEMBL3009752 0.89 TRPV4 (0.45) TRPV4HSD11B1ALDH1A1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TRPV4 2844/4885HSD11B1 1034/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.